News

MORRISTOWN, NJ, (September 17, 2018) BioAegis Therapeutics Inc. announced that it has begun patient enrollment in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in Community-Acquired Pneumonia (CAP) in Australasia.* The clinical-stage company is focused on a novel approach to address infectious, inflammatory and degenerative diseases through a portfolio built around rhu-pGSN technology. Separately, […]

MORRISTOWN, NJ (BIOAEGIS THERAPEUTICS) June 19, 2018.  BioAegis Therapeutics Inc., a clinical-stage company focused on developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around recombinant plasma gelsolin (rhu-pGSN) technology presented data at ASM-Microbe 2018 demonstrating that low admission plasma gelsolin concentrations can help identify community-acquired pneumonia (CAP) patients at high risk

New Patents Issued Across Multiple Geographies in US, Europe and Japan BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2017) BioAegis Therapeutics announces that during 2017 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in inflammatory disease, neurological disease and renal failure in the United States, Europe and Japan.

The recent review article, “Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus” in the November 15, 2017 Clinical Infectious Diseases, addresses the trends and current status of the etiology of Community Acquired Pneumonia (CAP). These data support the need for a pathogen-agnostic/host-based approach to the disease,

MORRISTOWN, NJ and BOSTON, MA, (BIOAEGIS THERAPEUTICS) October 18, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN) in augmenting innate immunity, announced that data demonstrating that “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” was presented during ID Week, on October 4-8, 2017 in

BOSTON, MA and MORRISTOWN, NJ (BIOAEGIS THERAPEUTICS) October 13, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN) in augmenting innate immunity announced that Mark J. DiNubile has joined the organization as Chief Medical Officer. Dr. DiNubile brings to BioAegis the rare combination of clinical and research expertise

BOSTON, MA, and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) September 30, 2017. BioAegis Therapeutics Inc. announced that founding scientist Dr. Thomas P. Stossel presented the 24th Annual William C. Maloney Lecture on September 28, 2017 in the Bornstein Amphitheater at the Brigham and Women’s Hospital. The invited lecture was entitled, “Can our 10th Most Abundant Plasma Protein

BioAegis Therapeutics, Inc. will present to investors at the Marcum Microcap Conference on June 15, 2017. This conference is a nationally recognized forum for private and publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. It draws

BioAegis Therapeutics, Inc. will present at the Cavendish Global Health Impact Forum in Washington, DC. on May 8, 2017. BioAegis’ technology was chosen as one of the groundbreaking discoveries and innovations at a program billed as “United for Impact: A Multi-sector Collaboration to Transform Health and Lifesciences.” Cavendish brings together participants that “share a passion

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 25, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), presented at the MACRO Trends Conference in Antwerp, Belgium  Presenting for the company was Mr. Steven Cordovano Co-Founder and Vice President of Investor Relations. Read the full press release here: MACROTRENDS Cfx 2017